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Abstract Opioid addiction has become a global epidemic and a national
health crisis in recent years, with the number of opioid overdose fatalities
steadily increasing since the 1990s. In contrast to the dynamics of a typi-
cal illicit drug or disease epidemic, opioid addiction has its roots in legal,
prescription medication - a fact which greatly increases the exposed popula-
tion and provides additional drug accessibility for addicts. In this paper, we
present a mathematical model for prescription drug addiction and treatment
with parameters and validation based on data from the opioid epidemic. Key
dynamics considered include addiction through prescription, addiction from
illicit sources, and treatment. Through mathematical analysis, we show that
no addiction-free equilibrium can exist without stringent control over how opi-
oids are administered and prescribed, effectively transforming the dynamics of
the opioid epidemic into those found in a purely illicit drug model. Numerical
sensitivity analysis suggests that relatively low states of endemic addiction can
be obtained by primarily focusing on medical prevention followed by aggres-
sive treatment of remaining cases - even when the probability of relapse from
treatment remains high. Further empirical study focused on understanding the
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rate of illicit drug dependence versus overdose risk, along with the current and
changing rates of opioid prescription and treatment, would shed significant
light on optimal control efforts and feasible outcomes for this epidemic and
drug epidemics in general.
Keywords Population Biology · Dynamical Systems · Epidemiology · SIR
Compartmental Model · Mathematical Biology · Prescription Drug Addiction
1 Introduction
Starting in the mid 1990s, allegations arose that the medical field systemati-
cally under-treated pain, and the American Pain Society lobbied to have pain
recognized as a 5th vital sign which, if adopted, would require all physicians
to accept and treat patient pain reports - naturally leading to an increase
in opioid prescriptions and increasing profits for drug manufacturers [61,31].
Meanwhile, confounding medical literature appeared suggesting that cancer
patients using prescription opioids to treat their chronic pain did not become
addicted [40,37,45]. One study found that only 1 participant out of 550 devel-
oped an addiction to their prescription painkillers [45]. Another study found
no cases of addiction among 10,000 burn victims using prescription opioid
drugs [37]. With this data, it began to appear as though physicians could
safely prescribe opioids to those in chronic pain without fear of addiction.
By 2000, the Joint Commission began requiring that health care organiza-
tions assessing and treat pain in all patients [31]. OxyContin prescriptions for
noncancer-related pain increased from 670, 000 in 1997 to nearly 6.2 million in
2002 [61]. This trend continued through the early 2000s, and in 2012, it was
discovered that 259 million opioid prescriptions had been written - enough for
every adult in America to have at least one bottle of pills [11]. By 2014, almost
2 million Americans abused or were dependent on prescription opioids [22].
Unfortunately, the increase in opioid prescriptions has led to an increase in
opioid addiction and abuse, affecting all age demographics. Large quantities
of unused prescription drugs are currently available in many prescribed users’
homes [4], and in 2015, 276, 000 American adolescents were abusing painkillers
for non-medical reasons [22] - many of whom obtained them from a friend or
relative who had a prescription [52,18]. In older age groups, regular, long-
term opioid use is more common [8] with possibly 1 in 4 long-term opioid
users struggling with addiction [6]. Geographically, the opioid epidemic not
only affects densely populated areas, but hits rural areas especially hard as
well [27].
Misconceptions regarding prescription opioids make them especially dan-
gerous and include the following: (1) Since opioids are medically prescribed
they are safe, (2) you cannot get addicted to prescription painkillers if taken
as prescribed, (3) a person is able to safely self-medicate for pain with opi-
oids, (4) only long-term use of certain opioids produces addiction [52,55]. The
coupling of these misconceptions with the general availability of opioids makes
this epidemic unlike previous drug waves. To make matters worse, many opioid
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addicts switch to heroin as a cheaper alternative to prescription opioids [32],
with estimates suggesting that as many as 4 out of 5 new heroin users had
abused prescription painkillers prior to starting heroin [25]. This is contrary to
previous trends of addiction moving from heroin use to prescription painkillers
abuse in the mid-1950s [23,29].
As of October 26, 2017, the US Department of Health and Human Ser-
vices has declared the opioid crisis a public health emergency [13]. Yet despite
the current seriousness and scale of the opioid epidemic, the need for effec-
tive intervention strategies, and an abundance of literature on mathematical
epidemiology for infectious diseases, rigorous mathematical theory has yet to
be applied to opioid addiction as it has for other diseases. In fact, very lit-
tle has been published applying mathematical epidemiology to the problem
of drug use in general. White and Comiskey [59] published perhaps the first
such model, mathematically describing the heroin epidemic as a system of
differential equations resembling the classic SIR model of Kermack and McK-
endrick [26]. Alterations of this model were subsequently studied by several
authors including [34,44,21,5,30], all targeting heroin. In 2012, Njagarah and
Nyabadza [33] described a model exploring the dynamics of drug abuse epi-
demics more generally, focusing on the interplay between light users, heavy
users, and rehabilitation. However, to the authors’ knowledge, no one has de-
veloped a compartmental differential equation model specifically for prescrip-
tion opioids with the intent of better understanding the dynamics involved.
In this paper, we investigate the dynamics driving the opioid epidemic by
formulating and analyzing an SIR-type model [26,1] built specifically to study
addiction to a general class of prescription drugs. Our model includes multiple
routes leading to dependency and addiction that are specific to prescription
medication, including a “prescribed” class that both directly feeds the addicted
population and contributes secondary cases via unsecured or unused drugs.
We then analyze the model for key properties and conditions that may lead
to a meaningful reduction in the number of addicted people and discuss our
conclusions. The goal of this paper is to investigate broad trends in prescription
opioid addiction rather than localized interactions in order to narrow down
possible global strategies for arresting the epidemic long-term.
2 Mathematical Methods
We begin by defining 4 population classes:
1. S (“susceptibles”): This is the general class of individuals who are not using
opioids or actively recovering from addiction.
2. P (“prescribed users”): This class is composed of individuals who are pre-
scribed opioids but do not have an addiction to them. Members have some
inherent rate (α) of becoming addicted to their prescriptions, and a rate
of finishing their prescription without addiction ().
3. A (“addicted”): All addicted opioid users are here, regardless if their drugs
are prescribed. There are multiple routes to this class in our model. One is
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prescription-induced (γ) addiction, while two others routes bypass P: one
based on interactions with addicted users or their dealers (β(1 − ξ)) and
another based on interactions with opioid patients (βξ), e.g. unsecured or
extra drugs [4]. Addicted users enter treatment at rate (ζ). Here, we define
an addicted individual as someone exhibiting a pattern of continued non-
medical use with potential for harm [56]. We will assume throughout this
paper that the term “pain reliever use disorder”, which appears regularly
in government reports [22], satisfies this definition and that persons who
“misuse” prescription opioids without further explanation do not satisfy
the definition.
4. R (“rehabilitation/treatment”): This class contains individuals who are in
treatment for their addiction. We include an inherent rate of falling back
into addiction (σ) as well as a mode of relapsing due to general availability
of the drug (ν). This in contrast to White and Comiskey [59] who only
allow for the latter approach. Also different in our model: members of
the recovering class who complete their treatment (at rate δ) return to
being susceptible. That is, we assume successful treatment does not impart
permanent immunity to addiction.
Fig. 1 Opioid Model Schematic. A schematic diagram showing the relationships be-
tween all the classes in the compartmental model of opioid addiction given by Eqns. 1-4.
Red arrows denote death rates, which are passed back into S to maintain a constant popu-
lation
The system is illustrated in Fig. 1 and is specified via four continuous-time
differential equations
S˙ = −αS − β(1− ξ)SA− βξSP + P + δR+ µ(P +R) + µ∗A (1)
P˙ = αS − (+ γ + µ)P (2)
A˙ = γP + σR+ β(1− ξ)SA+ βξSP + νRA− (ζ + µ∗)A (3)
R˙ = ζA− νRA− (δ + σ + µ)R. (4)
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where S + P + A + R = 1 and S, P,A, and R represent the mean expected
fraction of the population for each class. Time t is understood to be in years,
and all rates can be assumed to be yearly rates.
We assume that any mortality due to opioid-related overdose is insuffi-
cient to significantly change total population proportions (S,P ,A, and R),
and all deaths are recycled back into the S class to maintain the relation
S + P + A + R = 1. Additionally, we attempt to simply the system by con-
sidering only a first-order addiction rate γP from the P class to the A class,
assuming that prescribed medication (perhaps from multiple doctors) is the
primary source of opioids for most of these users. Second order effects due to
mass action with A and other members of P in the P → A route would likely
also need to include feedback effects including a dynamic whereby large num-
bers of addicted promote additional caution in the prescribed and susceptible
class, and we felt that this study was beyond the scope of a first model for
prescription opioid addiction. One exception to this thinking was made for
the νRA mass-action term, as we wanted to consider possible peer pressures
involved in making a successful recovery from addiction. This term represents
a balance between the negative influence of prescribed users and the possibil-
ity that they would take actions to prevent a recovering addict from accessing
their opioids, and so we did not include a RP term. In any case, our results
suggest that the model is quite insensitive to the choice of ν compared to σ,
and so this term would be a good candidate for omission in future studies.
We estimated parameter values from the literature wherever possible with
the goal of focusing our attention on a neighborhood of likely values. These
estimations are given in Table 1.
The 2017 CDC Annual Surveillance report states that in 2016, 19.1 out of
100 persons received one or more opioid prescriptions [10]. As some of these
will have been continuing patients from the previous year, we assume that α,
our yearly rate of moving from S to P , is less than 19.1. We were unable to
find more specific data on this rate and so estimated that α = 0.15. , the rate
of ending opioid prescription use per prescription user-year, was even more
difficult to find data on. Most patients end opioid use in less than a month,
while a smaller fraction can continue using opioid for over three years [48]. For
this reason, we explored a range of values for  from 0.8 to 8 representing a
general belief that most users will quit using prescription opioids in under a
year if they have not become addicted.
Our prescription-induced addiction rate (γ = 0.00744) is based off of a
comprehensive review [56] which sifted through many opioid patient addiction
studies of varying quality and methodology and found significant variance in
the addiction rates of prescription opioid users who had been on their pre-
scriptions for at least 90 days (95% confidence interval would have a rate
of approximately 0.057-0.169 in an unweighted collection of studies). Taking
only the high quality studies and an average of the minimum and maximum
percents, we estimated that 9.3 percent of chronic, non-cancer pain patients
become addicted to their opioid prescriptions. Using data that 0.75 of people
using prescription opioids for 3 months go on to use for a year and that 0.06 of
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all initiates to prescription opioids use for a year [48], we arrived at our value
for γ as a rate for addictions per prescribed user-year.
We then derived an illicit-induced addiction rate (β = 0.0036) based on
the ratio of physician-based sources of prescription opioids to other sources
among adults reporting prescription opioid use disorder [18], and given that
the Substance Abuse and Mental Health Services Administration (SAMHSA)
suggests that 2.1 million people abused prescription opioids for the first time
in 2015 out of a population of 320 million [22]. Using this same source data
[18], β was then further subdivided by differentiating the cases in which a
user primarily obtains opioids from friend/relative/other (ξβ) or from a source
related to general addictive demand (drug dealers/strangers) ((1−ξ)β), where
ξ was estimated to be 0.74. These parameter estimates are only meant to be
rough starting points for the purpose of basic analysis, particularly as we
expect these numbers to vary with both time and location.
The literature broadly suggests that approximately 90% of those entering
treatment relapse during the first year in recovery [49,2,58]. While we assume
that this rate would be lower if the overall supply and demand of illicit drugs
was reduced, it is hard to tease out to what extent. Acute stage withdrawal
lasts at most a few weeks [16], and studies on heroin addicts suggest that up to
70% of recovering addicts may relapse during the first month after treatment
ends [49,2]. A study on US prescription opioid addicts (no heroin) similarly
found that 8 weeks after cessation of treatment, only 9% had not relapsed [58].
We could not find published data on 4 weeks post-treatment. Therefore, we
took the timescale of recovery and relapse to be approximately one year and
made an estimate of 0.7 for the base relapse rate σ. This estimate is based on
the assumption that if there is no relapse within the first weeks, relapse is either
due to factors other than primary withdrawal or that there will be no relapse.
ν, the relapse rate ascribed to the presence of other addicted individuals,
was then assigned a value of 0.2 so that σ + ν = 0.9, the estimated yearly
proportion of R that relapse. While this is certainly a very rough estimate that
neglects factors such as post-acute withdrawal and discrepancy in treatment
methodology over both time and location, we believe it to be a reasonable
enough guess to serve as a gross estimate in this first model.
To estimate µ∗, the overall death rate for prescription opioid addicts, we
took a rough estimate of the number of prescription opioid deaths attributed
to addicted individuals, 54.6% [17], multiplied it by the prescription opioid
death rate for the entire population [47], and then normalized the result to
find the rate of prescription opioid deaths for the addicted class [22]. We then
added the natural death rate µ into it [28], e.g.
µ∗ = 0.546×
(
5.2
100, 000
)
×
(
300
2.0
)
+
(
728.8
100, 000
)
= 0.01155.
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Table 1 Table of estimated parameters for the opioid model (all rates are per-
capita yearly rates)
Description Est. Value Ref.
α prescription rate per person per year 0.15 [10]
 end prescription without addiction (rate) 0.8− 8 [48]
β total illicit addiction rate for S-class 0.0036 [18,22]
ξ fraction of β due to P 0.74 [18]
γ prescription-induced addiction rate 0.00744 [56,48]
ζ rate of A entry into rehabilitation 0.2–2
δ successful treatment rate 0.1 [58]
ν relapse rate of R-class due to A 0.2 [49,2]
σ natural relapse rate of R-class 0.7 [49,2]
µ natural death rate 0.007288 [28]
µ∗ death rate of addicts 0.01155 [17,22,28,47]
3 Results
The model was validated against national data for prescription opioid deaths
between 1999 and 2016 [19]. To estimate the proportion of these fatalities that
could be attributed specifically to addicted individuals rather than misuse by
others, we adopted the percentage of prescription opioid deaths (54.6%) at-
tributed to persons who had one or more high-risk factors, such as greater
than 4 prescribers, 4 different pharmacies, or a daily dosage greater than 100
morphine milligram equivalents (MME) [17]. Simulations were then carried
out using the estimated parameter values from Table 1 (see Fig. 2) and initial
conditions chosen to approximate the proportion of each model compartment
class present in 1999 (see Appendix A.1). In each simulation, we varied the
rates of ending opioid prescriptions without addiction () and treatment initi-
ation (ζ). The number of simulated opioid related deaths were then found by
computing pop(t) × (µ∗ − µ)A(t), where pop(t) was computed by taking the
US population between 1999 and 2016 and finding the best fit line through
the data [53].
Each color in Fig. 2 corresponds to a particular  value with ζ ∈ [0, 1]. Our
model generally agrees with the data for over a range of  and ζ values. Addi-
tionally, we explored which combinations of α, , and ζ would exactly predict
the number of 2016 opioid overdose deaths attributed to individuals who are
addicted. These relationships are found in Fig. 3. A few of the points on the
feasibility curves were also chosen to highlight population fractions within real-
istic ranges. For example, when α = 0.05,  = 0.30, and ζ = 1.069, we find pop-
ulation fractions of S(2016) = 0.8517, P (2016) = 0.1353, A(2016) = 0.0057,
and R(2016) = 0.0072. Or when α = 0.25,  = 5.30, and ζ = 0.183, we pre-
dict population fractions of S(2016) = 0.94, P (2016) = 0.0446, A(2016) =
0.0057, and R(2016) = 0.0012. Roughly 2 million Americans had a sub-
stance abuse disorder involving prescription opioids in 2016, hence roughly
2 × 106/300 × 106 US Pop = 0.0066 of Americans were actually addicted to
prescription opioids, though this number is for the entire year. Between 1998
and 2006, one estimation for P is that 2% of adults were taking an opioid in
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Fig. 2 Model Validation. Validating the model for varying  ∈ [1, 4] and ζ ∈ [0, 1] against
prescription opioid death data from [19]
any given week [7], so we might expect the actual value for P to be somewhat
greater than 0.02 in 2016.
Fig. 3 Model Validation. Validating the model for varying  ∈ [1, 4] and ζ ∈ [0, 1] against
prescription opioid death data from [19]
3.1 Addiction-free equilibrium
Existence of an addiction-free equilibrium (AFE) is dependent on the condition
that γ = 0, and either that β = 0 or ξ = 0. If β = 0, opioids are no longer
available anywhere in our model causing addiction to die out and remain
extinct since γ = 0 as well. If ξ = 0 instead, opioids are available only because
of demand from current addicts through the black market - essentially reducing
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the model to a sub-case that is applicable to any non-prescription illicit drug
epidemic. In this case, the AFE is given by
S∗ =
+ µ
α+ + µ
, A∗ = 0,
P ∗ =
α
α+ + µ
, R∗ = 0.
(5)
Traditionally, the basic reproduction number denotes how many secondary
infections result from one infected individual within a population. When R0 >
1, the epidemic is expected to grow as more infections occur while for R0 < 1,
the number of infected individuals declines. This remains consistent in the
context of drug epidemics: R0 may be calculated and denotes how many ad-
dictions there will be in the next generation (year) compared to the current
one. Assuming that γ = 0, ξ = 0 and β > 0, R0 can be found using the next
generation method [20,14]:
R0 = β(+ µ)
(α+ + µ)(µ∗ + ζΛ)
=
βS∗
µ∗ + ζΛ
where Λ =
δ + µ
δ + µ+ σ
, S∗ =
+ µ
α+ + µ
.
(6)
A derivation of this result is given in Appendix A.3, and is confirmed by Ja-
cobian analysis in Appendix A.4. For parameter values estimated in Table 1,
R0 < 1, and so in the absence of prescription-based primary and secondary
addictions, we actually expect the opioid epidemic to die out on its own. This
result reinforces conventional wisdom that unlike previous drug epidemics,
prescription opioid addiction is essentially a by-product of primary and sec-
ondary addictions caused by medical prescription and likely would not be
self-sustaining absent these prescriptions.
Another potentially surprising result of this calculation is that increasing
α, the rate at which opioids are prescribed to the general population, actually
reduces R0 and can thus act as a control on the epidemic. This behavior is a
direct result of the assumption that ξ = 0 and γ = 0, which are requirements
for the existence of the AFE. If no prescribed users can become addicted
to their drugs and their prescriptions do not cause other people to become
addicted either (perhaps through tight controls and monitoring), then the
prescribed class effectively becomes a safe haven from opioid addiction.
To analyze the bifurcation of this system with respect to β whenR0 = 1, we
follow the method described by Castillo-Chavez and Song [9] and demonstrated
by White and Comiskey [59]. Let Γ = ζ/(δ+µ+σ), and Λ = (δ+µ)/(δ+µ+σ).
Then whenever
ΛΓν > (1 + Γ )(µ∗ + ζΛ), (7)
a backward bifurcation occurs (see Jacobian Analysis for details of the cal-
culations). Practically speaking, this implies that when Eqn. 7 is satisfied,
a positive, stable, endemic equilibrium exists simultaneously with the stable
AFE, raising the possibility that additional effort beyond achieving R0 < 1
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may be required to eliminate addiction. For our estimated parameters in Ta-
ble 1, a backward bifurcation does not occur.
3.2 Numerical Sensitivity Analysis
To assess the overall 10 year sensitivity of the model to its parameters, we
used Saltelli’s extension of the Sobol sequence [42,43] to vary each parameter
within a range about its estimated value. We then conducted Sobol analysis
of variance [50] on the resulting values of S, P,A, and R after 10 years. Initial
conditions were chosen to reflect estimations of recent U.S. population fractions
in each class around the year 2016: P0 = 0.05 [7] (some increase added for
passage of time), A0 = 0.0062 [22], and R0 = 0.0003 [51] resulting in S0 =
0.9435 so that S+P +A+R = 1. Relative sensitivity of the parameters can be
seen in Fig. 4, where longer bars of a given color denote higher sensitivity to
that parameter. The reported results for all sub-bars in this figure are within
a 95% confidence interval of 0.0056. For parameter sensitivity analysis with
respect to the model’s AFE, see Appendix A.5.
*
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
First-order indices
S
P
A
R
*
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
Total-order indices
S
P
A
R
Value Range
.02-.2
.00114-.0114
0-1
.8-8
.00235-.0235
0-1
.2-2
0-1
.002305-.02305
* .003652-.03652
0-1
Fig. 4 Sensitivity of 10 year values for S, P,A, and R to model parameters. See
Fig. 1 or Table 1 for parameter definitions. First-order indices do not take into account
interactions with other parameters, while total-order indices measure sensitivity through all
higher-order interactions
3.3 Simulation Results Around Realistic Parameters
The parameters  (the rate at which prescribed persons complete their opioid
prescription(s)) and ζ (the rate that addicts enter treatment) are difficult to
parse out from data so in the following results, we varied them in the space of
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Fig. 5 Varying the Illicit Addiction Rate (β), Prescription Addiction Rate (γ),
Treatment Success Rate (δ), Prescription Rate (α), and Method of Relapse (κ).
Colormaps illustrate the predicted 10 years addicted population fraction for prescription
completion rates () and rehabilitation rates (ζ) between [0.8,8.0] and [0.2,2.0], respectively,
while varying the other parameters one at a time
, ζ ∈ [0.8, 8.0]×[0.2, 2.0] while simultaneously considering changes in one other
parameter at a time: β, δ, α, γ, and κ where κ = ν/(1−δ) is the ratio of relapse
back into addiction attributable to illicit usage (ν) over the total relapse rate (δ
is held constant when changing κ and ν/(1−δ)+σ/(1−δ) = κ+σ/(1−δ) = 1,
so κ gives the fraction of relapse due to ν vs. σ). The combined results are
shown in Fig. 5. Whenever unspecified by the plot, all parameters were held
constant as in Table 1 except in the case of δ and κ, where it was assumed
that ν + σ + δ = 1. In the case of δ, it was assumed that ν and σ maintain
their original ratio from Table 1 (ν = (2/9)(1− δ) and σ = (7/9)(1− δ)), and
in the case of κ, δ was held constant.
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The first row of Fig. 5 examines the effect of varying the overall rate of
obtaining illicit opioids (β) while holding ξ = 0.74, which dictates the source of
the drugs. As suggested by Fig. 4, model results do not appear to be sensitive
to ξ and so it was not included in Fig. 5. To minimize the number of opioid
addicts, a high prescription completion rate and a high rate of entering treat-
ment is required. As β increases, there exists a higher addicted class for low
values of  and ζ, suggesting that illicit opioids could exacerbate the number of
addicted in certain circumstances - a scenario that was not apparent from the
Sobol analysis in Fig. 4 which was conducted within a larger feasibility space
of all parameters rather than the estimated values in Table 1. However, as
suggested by Fig. 4, the model seems less sensitive to β than other parameters
explored by Fig. 5.
On the other hand, the second row of Fig. 5 suggests that for estimated
parameters the rate at which medically prescribed opioid users become ad-
dicted (γ) very significantly affects the number of addicted. When γ doubles
from its assumed realistic value of 0.00744 to 0.015, the number of addicts
virtually doubles as well. For small differences in κ, the system is not particu-
larly sensitive to how addicts relapse, either on their own (σ) or based on total
illicit usage and availability (νA), but if σ can be made small relative to ν, the
number of addicted persons can be expected to fall - an unsurprising result
given that ν appears in a second order term (νRA) while σ appears in a first
order term (σR). Further analysis, including how each of these parameters
affect compartments other than A can be found in the Appendix.
Finally, we explored the relationship between α, , δ, and ζ in detail, as
these parameters are most likely to be the target of control efforts. The results
can be seen in Fig. 6.
4 Discussion and Conclusion
In this paper, we present a first model for the opioid epidemic which utilizes
the successful mathematical epidemiology approach popularized by Kermack
and McKendrick in 1927 for the spread of infectious disease [26]. Parameters
are estimated from the literature and simulation results are compared with
mortality data and estimates for current population fractions of our given
model compartments. Analysis of our model shows that maintenance of an
addiction-free population (the addiction-free equilibrium, or AFE) requires
at minimum the elimination of both patient prescription-induced addiction
(γ = 0) as well as secondary, non-patient addictions attributable to filled
prescriptions (ξ = 0). Parameter sensitivity analysis indicates that the first
of these is far more important, with near-AFE endemic states possible even
if ξ is significantly greater than zero as long as γ = 0 (see Appendix 7). This
result strongly suggests that reducing the number of addictions among opioid-
prescribed patients is a critical first step in combating the crisis.
Even if in the hypothetical case that both prescription induced addiction
and addiction resulting from leftover prescription opioids was eliminated, the
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Fig. 6 Varying the the Prescription Rate (α) and Treatment Success Rate (δ)
in tandem with varying prescription completion rates () and rehabilitation rates (ζ) be-
tween [0.8,8.0] and [0,1]. Colormaps illustrate the predicted 10 years addicted population
percentage
threat of ongoing, endemic addiction persists due to illicit availability of these
drugs. In this case, our model reduces to a classic illicit drug addiction model
except that prescribed opioid users are considered safe from addiction since
they are closely monitored to prevent addiction to the drugs they are taking.
Our calculation of the basic reproduction number, R0, then provides a metric
by which we can determine if overall addiction will eventually die off or persist
based upon model parameters.
Due to the form discovered for R0 (Eqn. 6), the ratio of addiction to illicit
opioids (β) to the death rate of addicts (µ∗) appears to be critical. If this ratio
is less than one, as it is for our parameter estimates, the opioid epidemic is not
self-sustaining without prescription drugs no matter the prescription rate or
addiction treatment rate. This precise ratio β/µ∗ may be somewhat artificial
due to the recycling of overdosed persons back into the susceptible class (done
in order to maintain an overall static population size). But the suggestion of
a natural balance between a drug’s infectiousness and potential for addiction
verses its potential to be lethal is not far-fetched and could merit further study
to better understand addiction in the context of an infectious social disease.
In parameter regimes where R0 ≥ 1, we note the importance of entry into
rehabilitation (ζ), particularly as the rehabilitation success rate grows (δ) and
the natural tendency to relapse shrinks (σ). This is evidenced both by the
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parameter sensitivity analysis in Fig. 4 which highlights ζ as a key parameter
for the addicted class and Eqn. 6, where we see that the effect of ζ on R0 is
regulated by σ and δ.
Given the difficulties of completely eradicating prescription-based addic-
tion (γ = 0 and ξ = 0), the idea of reaching an addiction-free state remains im-
probable. Relaxing these assumptions, our results suggest that control efforts
should focus on reducing the average prescription length () and increasing the
rate addicts enter treatment (ζ), even if treatment is often unsuccessful (Fig.
5), followed by decreasing the number of prescriptions written (α). Reducing
both  and α could help naturally decrease the rate of prescription-induced
addiction, γ. In one typical case where  = 3.0 and ζ = 0.25, doubling the
rate that users enter treatment to ζ = 0.5, resulted in a 23.5% decrease in the
addicted population after 5 years, despite the fact that treatment success was
held at 10%. If the treatment success rate doubles to δ = 0.2, the addicted
population decreases another 9.3% (or by 30.5% of where it was initially) after
5 years.
Following this, we found that increasing the success rate of rehabilitation
(δ) should also be a priority (Fig. 10 in the Appendix). It is interesting to
note that decreases in the overall length of prescriptions (increasing ) have
the most effect when  ≥ 1.5. The beneficial effect of decreasing overall the
prescription lengths is particularly pronounced when either the rate of start-
ing rehabilitation (ζ) is low or the success rate of rehabilitation (δ) is low,
regardless of the prescription rate (α) . On the other hand, our model sug-
gests that neither the mode of relapse nor the origin of illicit opioids, whether
from leftover prescriptions or demand-driven market, has much impact on the
total fraction of addicted (Fig. 4, and Figs. and 7 and 12 in the Appendix).
To simplify the dynamics for this first model, we neglected potential effects
due to gender, race, and geographical location. Additionally, our model did not
attempt to capture how prescription drug addicts may move to heroin or vice
versa, leaving this study to future work. This dynamic has important ramifica-
tions for public health as heroin use is associated with high rates of overdose,
especially when laced with fentanyl [15,38,35], and could be particularly lethal
for users who have first built up an opioid tolerance and then increase their
doses on heroin [32]. While many have modeled the heroin epidemic previ-
ously [12,59,3,34,21,60], we are not aware of studies that incorporate effects
of fentanyl, methadone, and prescription opioids all together, or studies that
explicitly consider demographic effects. Our model is meant to provide a start-
ing point for this larger, more detailed work.
Another simplification we made for the presentation of this first model
was the implicit assumption that parameter values are constant with respect
to time. This is obviously not the case in for many of our parameters, in
particular the prescription initiation rate (α) [39], the prescription completion
rate () [46], the rehabilitation initiation rate (ζ), and the rehabilitation success
rate (δ). Despite the large amount of public interest in prescription opioid
addiction, we found it quite difficult to obtain our ball-park estimates for
many of the parameters, as prescription and addiction statistics are often given
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in yearly aggregate numbers and survey studies are not typically designed
with the intent to parameterize mathematical models. For other parameters
such as β, ξ, and ν, data is almost wholly absent by nature; fortunately, our
results suggest that the model is relatively insensitive to these parameters.
While beyond the scope of this particular study, we believe that a rigorous,
time-sensitive estimation of model parameters is an important next step and
represents a significant work on its own.
In summary, our main results confirm that necessary measures to combat-
ing the opioid epidemic include lowering the number and duration of medically
prescribed painkillers, more successful treatment regimens, and increasing the
availability, ease, and motivation for opioid addicts to enter treatment [57].
Our findings also provide a direct measure of the epidemic’s sensitivity to
each of these efforts which may be useful in allocating available resources, es-
pecially for small rural towns, cities, or states combating the epidemic. Better
estimates of model parameters from data could prove crucial in developing
management strategies and refining our modeling approaches - given the role
of non-prescription opioids such as heroin and fentanyl to the overall epidemic
and the unique effects of geography and population demography, we believe
that the model presented here represents only the beginning in a larger math-
ematical exploration of opioid addiction dynamics.
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A Appendix
Here we present supplemental material to support our findings including additional model
analysis and validation, numerical stability analysis, and simulation data. We also provide
details for the calculation determining a condition for backward bifurcation, the explicit
Jacobian used in our stability analysis, and simulation results illustrating system sensitivity
to the prescription addiction rate (γ), treatment success rate (δ), prescription rate (α), and
method of relapse (κ). Futhermore, we explore the and the relationship between prescription
rate (α) and prescription addiction rate (γ).
A.1 Initial Conditions for Validation
We estimated the initial prescribed population, P0, based off of the percentage of U.S.
population to whom were prescribed opioids at any given week in 2009 (2%) [7]. Since there
were more prescriptions given in 2009 than 1999 [48], we estimated that roughly 0.40× 2%
of the population were prescribed opioids at any time in 1999, hence P0 = 0.008. Note we
estimated the coefficient of 0.40 by using the ratio of total opioids MME sold in 1999 to
2009 [54].
We backed out the initial addicted population from the number of prescription opioid
deaths in 1999 (2749) [19], and normalized it by the fraction of deaths attributed to addicted
persons (54.6%) [17] and the predicted number of deaths from our model with the age-
adjusted U.S. population in 1999 (259×106) [53], e.g., A0 = (0.546)(2749)(259×106)(µ∗−µ) = 0.00136. We
then assumed R0 = 0.1A0 [36] (fraction of population in treatment), making S0 = 0.990504.
A.2 Analysis of the Addiction-Free Equilibrium
Here we derive conditions on the existence of an addiction-free equilibrium (AFE) within
the system defined by Eqns.1-4. To begin, we set each equation to zero and require that
A = 0. Eqn. 3 becomes 0 = −(δ + σ + µ)R, and since µ > 0 as a natural death rate, this
implies that R = 0 at any AFE (conversely, R = 0 requires that either A = 0 or ζ = 0,
which my apply at the beginning of an epidemic). We are left with the system
0 = −αS∗ − βξS∗P ∗ + P ∗ + µP ∗
0 = αS∗ − (+ γ + µ)P ∗
0 = P ∗(γ + βξS∗).
We require that P 6= 0 since otherwise the only solution is S∗ = P ∗ = A∗ = R∗ = 0.
Then 0 = γ + βξS. Since all our parameters and dependent variables are non-negative by
definition, γ = 0 and either β = 0 or ξ = 0. If β = 0, opioids are no longer available
anywhere in our model, and so it is only natural that the addiction state dies out. If ξ = 0,
opioids are available only through the presence of current addicts (e.g. on the black market
due to illicit demand) and not through currently prescribed users. In this case, we can use
our assumption that 1 = S + P +A+R to find that
S∗ =
+ µ
α+ + µ
A∗ = 0
P ∗ =
α
α+ + µ
R∗ = 0.
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A.3 Calculating the Basic Reproduction Number, R0
Assuming that γ = 0 and ξ = 0, the necessary (if β 6= 0) and sufficient conditions for the
AFE to exist, Eqns. 3 and 4 reduce to
A˙ = σR+ βSA+ νRA− (ζ + µ∗)A
R˙ = ζA− νRA− (δ + σ + µ)R.
Using the next generation method [20,14] with both A and R treated as “infected”, we
compute the matrices F and V as
F =
[
β(+µ)
α++µ
0
0 0
]
and V =
[
ζ + µ∗ −σ
−ζ δ + σ + µ
]
.
Then R0 is given by the spectral radius of FV −1,
R0 =
β(+ µ)
(α+ + µ)(µ∗ + ζΛ)
=
βS∗
µ∗ + ζΛ
where Λ =
δ + µ
δ + µ+ σ
, S∗ =
+ µ
α+ + µ
.
Prevalence of opioid addicts will rise when R0 > 1 and fall when R0 < 1. This result is
confirmed by Jacobian analysis in Appendix A.4.
A.4 Jacobian Analysis
Before computing the Jacobian for the system 1-4, note that N (total number of individuals)
is constant in this model and equal to 1. Therefore the system reduces to three equations,
S˙ = −αS − β(1− ξ)SA− βξS(1− S −A−R)
+ (+ µ)(1− S −A−R) + (δ + µ)R+ µ∗A
A˙ = γ(1− S −A−R) + σR+ β(1− ξ)SA
+ βξS(1− S −A−R) + νRA− (ζ + µ∗)A
R˙ = ζA− νRA− (δ + σ + µ)R,
(8)
where P = 1− S −A−R. The Jacobian of this equation is given in Eqn. 9.
J =

−α− β(1− ξ)A+ βξ(S − P )− (+ µ) −β(1− 2ξ)S − (+ µ) + µ∗ βξS + δ − 
−γ + β(1− ξ)A+ βξ(P − S) −γ + β(1− 2ξ)S + νR− (ζ + µ∗) −γ + σ − βξS + νA
0 ζ − νR −νA− (δ + σ + µ)

(9)
We now focus the Jacobian evaluated at the AFE. Recall that the existence of this
equilibrium requires that γ = 0 and either β = 0 or ξ = 0. If γ = 0 and β = 0 there are no
opioids left in the model, so we assume β 6= 0 and that ξ = 0. Using these parameter values
and the AFE x0 given by Eqns. 5, J(x0) is−(α+ + µ) −
β(+µ)
α++µ
− (+ µ) + µ∗ δ − 
0
β(+µ)
α++µ
− (ζ + µ∗) σ
0 ζ −(δ + σ + µ)
 .
18 Nicholas A. Battista et al.
The characteristic polynomial is
p(λ) = −(α+ + µ+ λ)
[
λ2 +
(
ζ + µ∗ + δ + σ + µ− β(+ µ)
α+ + µ
)
λ
+
(
ζ + µ ∗ − β(+ µ)
α+ + µ
)
(δ + σ + µ)− σζ
]
.
The root λ1 = −(α +  + µ) is always negative since we assume that α,  ≥ 0 and
µ > 0. Thus, the AFE is stable if the remaining two roots have negative real part. Applying
the Routh-Hurwitz Stability Criteria [41,24] to the degree-two polynomial p(λ), stability
requires that
β(+ µ)
α+ + µ
< ζ + µ∗ + δ + σ + µ and (10)
β(+ µ)
α+ + µ
< ζ + µ∗ − ζσ
δ + σ + µ
= µ∗ + ζ
(
δ + µ
δ + µ+ σ
)
. (11)
All parameters are strictly non-negative, so Eqn. 11 implies 10. Furthermore, dividing both
sides of Eqn. 11 by the right hand size, one arrives at the R0 stability criterion. Numerical
stability results for the AFE further confirm this analysis and are given in Appendix A.5.
To analyze the bifurcation of this system when R0 = 1, we follow the method described
by Castillo-Chavez and Song [9] and demonstrated by White and Comiskey [59] to determine
the bifurcation’s direction. Given the form of R0, we take β to be the bifurcation parameter
and conduct our analysis around
β∗ =
µ∗ + ζΛ
S∗
.
First, we define the matrix A as in [9] but, via a change of coordinates, taking x0 to be the
AFE and the bifurcation parameter to be β. Writing our system of differential equations as
dx/dt = f(x, β), we have
A =
∂fi
∂xj
(x0, β = β
∗) = J(x0, β = β∗)
=
−(α+ + µ) −ζΛ− (+ µ) δ − 0 ζ(Λ− 1) σ
0 ζ −(δ + σ + µ)
 . (12)
It is easy to check that zero is a simple eigenvalue of A and that all other eigenvalues of A
have negative real parts. A has right eigenvector x = (−S∗(1− Γ ), 1, Γ )T x2 where x2 is free,
Γ = ζ/(δ + µ+ σ), and Λ = (δ + µ)/(δ + µ+ σ). A has left eigenvector y = (0, 1, 1− Λ)y2,
where y2 is free. The first component of x is negative, but since S∗ > 0 the analysis still
applies [9]. Now we let fk be the kth component of f and set
a =
∑
k,i,j=1
ykxixj
∂2fk
∂xi∂xj
(x0, β = β
∗)
b =
∑
k,i=1
ykxi
∂2fk
∂xi∂β
.
Modeling the prescription opioid epidemic 19
The non-zero derivatives are
∂2f1
∂S∂A
=
∂2f1
∂A∂S
= −β∗
∂2f2
∂S∂A
=
∂2f2
∂A∂S
= β∗
∂2f2
∂A∂R
=
∂2f2
∂R∂A
= ν
∂2f3
∂A∂R
=
∂2f3
∂R∂A
= −ν
∂2f1
∂A∂β
= −S∗
∂2f2
∂A∂β
= S∗
and
a = (1)(−S∗(1 + Γ ))(1)β∗ + (1)(1)(−S∗(1 + Γ ))β∗ + (1)(1)Γν
+ (1)Γ (1)ν + (1− Λ)(1)Γ (−ν) + (1− Λ)Γ (1)(−ν)
= −2S∗(1 + Γ )β∗ + 2ΛΓν = −2(1 + Γ )(µ∗ + ζΛ) + 2ΛΓν
b = (1)(1)S∗ > 0.
To make a > 0, we therefore need
ΛΓν > (1 + Γ )(µ∗ + ζΛ). (13)
If this condition is satisfied, there will be a backward bifurcation at R0 = 1. Practically
speaking, this implies that when Eqn. 7 is satisfied, a positive, stable, endemic equilibrium
exists simultaneously with the stable addiction-free state, raising the possibility that addi-
tional effort beyond reducing R0 < 1 may be required to arrive at the addiction-free state.
For our estimated parameters (see Table 1), a forward bifurcation occurs for all ζ ≥ 0.
A.5 Addiction Free Equilibrium Numerical Analysis
To examine the sensitivity of the model’s addiction free equilibrium (AFE) to its parameters,
we first ran simulations to see how the AFE changes when either γ or ξ shifts away from
zero. Parameter values were chosen as in Table 1 with  = 3 and ζ = 0.25. Our results
show that for our estimated parameters resulting in R0 ≈ 0.085, shifting ξ away from zero
has little noticeable effect while shifting γ away from zero strongly moves the equilibrium
away from the addiction-free state (see Fig. 7). This suggests that in a nearly addiction-
free population, prescription-induced addiction remains far more important than securing
prescriptions away from non-prescribed users. Note that in the exact case of an AFE, it is
always stable when γ = ξ = 0 for a parameter space centered around the other parameters
listed in Table 1.
Further analysis of the model parameter space when γ = ξ = 0 was conducted using the
Sobol method [50]. We chose N = 800000 and generated N(2D + 2) parameter sets (where
D = 9 is the dimension of the parameter space) via Saltelli’s extension of the Sobol sequence
[42,43] for a total of 16 million samples. We then ran the model to 10000 years for each set
of parameters to arrive at an equilibrium. We subsequently conducted Sobol analysis [50]
on the values for S, P,A, and R after the final year. Initial conditions for each simulation
were S(0) = 0.9435, P (0) = 0.05, A(0) = 0.0062, and R(0) = 0.0003.
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Fig. 7 Model Sensitivity to γ and ξ. Effect of moving γ and/or ξ away from zero when
R0 ≈ 0.085 with likely parameter values,  = 3 and ζ = 0.25
*
0.0
0.2
0.4
0.6
0.8
1.0
1.2
First-order indices
S
P
A
R
*
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
Total-order indices
S
P
A
R
Value Range
0.03-0.3
0.0003-0.03
0.01-1
0.8-8
0.1-2
0.01-1
0.001-0.01
* 0.005-0.1
0.01-1
Fig. 8 Sobol sensitivity analysis for equilibrium values when γ = ξ = 0 (see Fig 1 or
Table 1 for parameter definitions). First-order indices do not take into account interactions
with other parameters, while total-order indices measure sensitivity through all higher-order
interactions. The parameter ranges tested here are the same as in Fig. 4
A.6 Further Numerical Exploration of Parameter Space
In this section we expand our parameter space exploration for {, ζ} ∈ [0.8, 8.0]× [0.2, 2.0] by
examining parameter sensitivity for each of S, P,A, and R instead of only the addicted class.
More specifically, we examine the associated effects of  and ζ on the predicted populations
for 10 years into the future for each of the following cases:
1. Prescription Addiction Rate (γ),
2. Treatment Success Rate (δ),
3. Prescription Rate (α),
4. Method of Relapse (κ) when ξ = 0.74
5. Prescription Rate vs. Prescription-Induced Addiction (α vs. γ).
As in Fig. 5, Fig. 9 shows that as γ increases the addicted population grows. In particular,
if γ doubles from its estimated value, there exists (, ζ) for which 2% of the population
becomes addicted to opioids, which is approximately three times the number of addicts in
Modeling the prescription opioid epidemic 21
2016. Moreover, as γ increases, so does the rehabilitation class. Interestingly, for values of
(, ζ) that make the addicted class roughly 2% of the population, the rehabilitation class
makes up approximately 1%. On the other hand, when the rehabilitation class composes
roughly 1.5% of the population, the addicted class makes up roughly the same percentage.
When δ increases the rehabilitation class population decreases near zero. The population of
the addicted class decreases towards zero as well, while the populations of the susceptible
class and prescribed class appear unaffected (Fig. 10).
Fig. 11 shows that if the prescription rate α is small enough, the entire population
almost remains in the susceptible class. However, for certain values of (, ζ) roughly 0.5% of
the population can still remain in the addicted population. Moreover, for all cases of α and
small ζ, the rehabilitation class’ population remains near zero for almost all values of .
Setting δ = 0.1, we let κ = ν/(1 − δ) be the fraction of relapse back into addiction
attributable to total illicit usage and availability. σ is then defined as σ = 1− δ − ν. Using
the parameters in Table 1, we explored the system’s sensitivity to κ. The simulation data is
presented in Fig. 12. Qualitatively, there are only subtle differences in the dynamics, but for
larger values of  and ζ, lowering σ relative to ν is more effective at diminishing the addicted
class.
Finally, we explore the relationship between prescription-induced addiction (γ) and com-
pleting the prescription and heading back into the susceptible class (). Situations in which
these two parameters do not add to one could be used to model long or short-term opioid
prescription use. The data is presented in Fig. 13. It is clear that a decrease in  corre-
sponds to an increase in the number of addicts as might be expected for more chronic opioid
prescription use. For large γ those differences are more subtle, as increasing γ leads to a
profound escalation in the addicted population regardless of .
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Fig. 9 Prescription Addiction Rate Colormaps illustrating the long-term equilibrium
solutions (S∗, P ∗, R∗, and A∗) for prescription-end rates () and rehabilitation-start rates
(ζ) between [0.8, 8] and [0.2, 2.0], respectively, and for various prescription addiction rates
(γ)
Fig. 10 Treatment Success Rate Colormaps illustrating the long-term equilibrium so-
lutions (S∗, P ∗, R∗, and A∗) for prescription-end rates () and rehabilitation-start rates (ζ)
between [0.8, 8] and [0.2, 2.0], respectively, and for various treatment success rates (δ)
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Fig. 11 Prescription Rate Colormaps illustrating the long-term equilibrium solutions
(S∗, P ∗, R∗, and A∗) for prescription-end rates () and rehabilitation-start rates (ζ) between
[0.8, 8] and [0.2, 2.0], respectively, and for various prescription rates (α)
Fig. 12 Relapse Due to Overall Illicit Usage and Availability. Colormaps illustrat-
ing the long-term equilibrium solutions (S∗, P ∗, R∗, and A∗) for prescription-end rates ()
and rehabilitation-start rates (ζ) between [0.8, 8] and [0.2, 2.0], respectively, and for various
ratios of relapse back into addiction due to overall illicit usage and availability over the total
relapse rate (κ)
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Fig. 13 Prescription-Induced Addiction vs. Prescription Completion. Colormaps
illustrating the long-term equilibrium solutions (S∗, P ∗, R∗, and A∗) for prescription rates
(α) and rehabilitation rates (ζ) between 0 and 1 and for various rates of prescription-induced
addiction (γ) and rates of finishing prescriptions ()
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